期刊文献+

Ki-67、C-erb-B2及nm23在前列腺癌中的表达及意义 被引量:6

Expressions of Ki-67、C-erb-B2 and nm23 in prostate cancer
下载PDF
导出
摘要 目的探讨相关癌基因等在前列腺癌中表达的意义,从病理学角度了解前列腺癌的生物学特性。方法根据最新WHO分类标准(2002)及Gleason分级法进行组织学分级和对比性分析;应用免疫组织化学技术,观察增殖细胞核抗原Ki-67、原癌基因c-erbB-2、抑癌基因nm23在前列腺癌中的表达情况。结果近81.69%的患者在Gleason分级8分以上;Ki-67与组织学分级之间有显著性差异,(P<0.05);肿瘤的恶性程度越高,肿瘤细胞的Ki-67表达越强;c-erbB-2随着肿瘤恶性程度增高,其阳性表达率也在上升(P<0.05),且c-erbB-2的阳性表达率与Gleason分级之间有显著性差异;nm23的阳性表达率与Gleason分级之间存在显著的差异性(P<0.05),Gleason分值越高,nm23阳性表达率也在增加。结论Ki-67、c-erbB-2、nm23可作为判断前列腺癌生物学行为即肿瘤预后的可靠指标。 Objective Purpose To explore the expression of Ki-67, c-erbB-2 and nm23 in prostate cancer and its significance respectively. Methods Immunohistochemical staining method was used to detect the expression of Ki-67, c-erbB-2 and nm23 in 113 prostate cancer cases. Results According to ~$ classification of WHO and Gleason grade, there were 81.69% cases G 〉 8. There were10.35% ,22.72% ,58.33% cases (G 〈 7,G = 7, G 〉 7) positive respectively for Ki-67 and 10.53%, 18.18% ,48.33% cases (G 〈 7,G= 7,G〉 7) positive for C-erbB-2. For nm23 expression was 36.84% ,45.45% ,73.33% cases (G〈 7,G = 7,G 〉 7) .And significant different was determined between three parameters and Gleanson grade respectively. Conclusion ' There were obvious rela- tionships among the expression of Ki-67, c-erbB-2, nm23 and Gleason grade. All P 〈 0.05, Ki-67, e-erbB=2, nm23 axe reliable pa- rameters for prognosis prostate cancer.
出处 《中国实验诊断学》 北大核心 2010年第1期90-92,共3页 Chinese Journal of Laboratory Diagnosis
关键词 前列腺癌 病理诊断 免疫组化 预后 prostate cancer pathological diagnosis, immunohistochemistry prognosis
  • 相关文献

参考文献4

二级参考文献26

  • 1何晓静,朱美玲,宋洁.银杏叶总黄酮对糖尿病大鼠视网膜细胞凋亡相关基因表达的影响[J].安徽医科大学学报,2006,41(3):283-285. 被引量:10
  • 2吴英恺.国际心胸外科实践[M].上海:上海科学技术出版社,1986.816-817.
  • 3Stravodimos, K., C. Constantinides, T. Manousakas, C.Pavlaki, D. Pantazopoulos, A. Giannopoulos, & C. Dimopoulos, 2000, Immunohistochemical expression of transforming growth factor beta 1 and nm-23H1 antioncogene in prostate cancer: divergent correlation with clinicopathological parameters. A nticancer Res., 20 (5) :3823-3828.
  • 4Roberts,A & Spom, M., 1996,Transforming growth factor β in molecular and cellular biology of wound repair,PAF Clank, Med. New York, Plenum Press., 43 (15) :275-308.
  • 5Jacquemier, J., M. P. Mathoulin-Portier, R. Valtola, E.Charafe -Jauffret, J. Geneix, G.Houvenaeghel, B. Puig,V.J. Bardou,J. Hassoun,P. Viens & D. Birnbaum,2000,Prognosis of breast carcinoma lymphangiogenesis evaluated by immunohistochemicnal investigation of vascular-endothelial-growth-factor recptor 3. Int. J. Cancer, 89(1): 69-73.
  • 6Akagi, K., Y. Ikeda, M. Miyazaki,T. Abe, J. Kinoshita,Y. Maehara & K. Sugimachi, 2000, Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer, 83: 887-891.
  • 7Weidner, N., J. P. Semple,W. R. Welch & J. Folkman,1991 ,Tumor angiogenesis and metastasis : correlation in invasive breast carcinoma. N. Engl. J. Med, 324: 1-8.
  • 8Kaplan, E. L & P. Meier., 1958, Parametric estimation from incomplete observation. J. Am. Star. Assoc. 53: 457 -481.
  • 9Steeg,P. S.,G. Bevilacqua & L. Kopper, 1988,Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Canaer.Inst, 80(3): 200-204.
  • 10Russell, R. L., A. N. Pedersen, J. Kantor, K. Geisinger,R. Long, N. Zbieranski, A. Townsend, B. Shelton, N.Brunne. & T.E. Kute, 1998, Relationship of nm23 to proteolytic factor,proliferation and motility in breast cancer tissues and cell lines. Br. J. Cancer, 78(6) : 710-717.

共引文献21

同被引文献86

  • 1李爱华,刘培淑.卵巢癌HER-2表达及其与临床病理学[J].中华肿瘤防治杂志,2006,13(6):476-478. 被引量:1
  • 2赵川,韩丹,杨友,金树珍.Bcl-2和P_(53)蛋白在前列腺癌组织中的表达及其意义[J].昆明医学院学报,2006,27(4):72-74. 被引量:8
  • 3Mhawech-Fauceglia P,Zhang S,Terracciano L,黄文斌(摘译).前列腺特异性膜抗原蛋白在正常和肿瘤组织中的表达及其在前列腺癌诊断中的敏感性和特异性[J].临床与实验病理学杂志,2007,23(3):261-261. 被引量:34
  • 4Epstein JI, Algaba F, Allsbrook WC, et al. Tumours of the prostate [ A ]. Eble JN, Santer G, Epstein JI, et al. World Health Organiza- tion classification of tumours. Pathology and genetics of tumours of urinary system and male genital organs [ M ]. Lyon: IARC Press, 2004 : 175 - 201.
  • 5Tefilli MV. Should Gleason score 7 prostate cancer be considered a unique grade category [ J ] ? Urology, 1999,53 (2) :372 - 377.
  • 6Ross JS, McKenna BJ. The HER2/neu oncogene in tumors of the gas trointestinal tract [ J]. Cancer Invest,2001,19:554.
  • 7Ratan HL, Gescher A, Stew and WP, et al. ErbB receptors possible therapeutic targets in prostate cancer [ J ] ? B J Int 2003,92 ( 9 ) : 890 - 895.
  • 8Montironi R, Mazzucchelli R, Barbisan F, et al. HER2 expression and gene amplificacion in pT2a Gleason score 6 prostate cancer in- cidentally detected in cystoprostatectomies comparison with clini- cally detected androgen - dependent and androgen - independent cancer[ J ]. Hum Pathol,2006,37 (9) : 1137 - 1144.
  • 9Charpin C, Discarie M J, Barbeau B, et al. Monoclonal 3 C6F9 distri- bution in human breast carcinomas image cytometry of immunocyto- chemical assays [ J ]. Med Oncol Tumor Pharmacother, 1991,8 (4) : 243 - 251.
  • 10Cowen D,Troncoso P, Khoo Vincent S, et al. Ki -67 staining is an independent correlate of biochemical failure in prostate cancer treated with radio therapy [ J ]. Clin Cancer Res,2002,49 ( 2 ) :93.

引证文献6

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部